FDA accepts review for ANGLE’s Parsortix system for metastatic breast cancer
System captures and harvests intact circulating tumour cells for analysis
Read More
Tag: Parsortix
Parsortix test could avoid unnecessary prostate biopsies
Currently, investigation of symptoms for prostate cancer is typically made via an invasive blood test.
Read More
Angle’s ovarian cancer test could beat current standard
UK liquid biopsy group Angle has released trial findings that indicate its Parsortix blood test has the potential to out-perform the current standard of care in detecting ovarian cancer.
Read More
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
- EnteroBiotix completes enrolment for trial of EBX‑102‑02
- Lundbeck completes patient randomisation early in global MSA trial
